AI English summary of an SEC filing — figures as filed

The company said on April 24, 2024 it temporarily expanded its board from 10 to 11 members and appointed Dr. Judith Klimovsky as an independent director. It said 10 of the 11 directors on the board after the appointment are independent.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Apr 30, 2024Period of report Apr 24, 2024Summary published (UTC) Oct 30, 2026

Key points

AI summary

The company said on April 24, 2024 it temporarily expanded its board from 10 to 11 members and appointed Dr. Judith Klimovsky as an independent director. It said 10 of the 11 directors on the board after the appointment are independent.
Bio-Techne said Dr. Klimovsky is currently Executive Vice President and Chief Development Officer at Genmab, and previously held senior clinical and research positions at Novartis Oncology and Bristol-Myers Squibb.
The company said Dr. Klimovsky will serve on the Science & Technology Committee and will receive director compensation under its standard non-employee director arrangements, pro-rated for a partial year of service.
The company said its board approved a waiver of the mandatory retirement policy for Dr. Roeland Nusse for 1 year.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Dr. Judith Klimovsky Appointed Independent Director; Board Composition

The company said on April 24, 2024 it temporarily expanded its board from 10 to 11 members and appointed Dr. Judith Klimovsky as an independent director. It said 10 of the 11 directors on the board after the appointment are independent.

Source · Based on the filing body and exhibits

Dr. Klimovsky's Background

Bio-Techne said Dr. Klimovsky is currently Executive Vice President and Chief Development Officer at Genmab, and previously held senior clinical and research positions at Novartis Oncology and Bristol-Myers Squibb.

Source · Based on the filing body and exhibits

Committee Assignment and Director Compensation Terms

The company said Dr. Klimovsky will serve on the Science & Technology Committee and will receive director compensation under its standard non-employee director arrangements, pro-rated for a partial year of service.

Source · Based on the filing body and exhibits

Waiver of Retirement Policy for Dr. Roeland Nusse

The company said its board approved a waiver of the mandatory retirement policy for Dr. Roeland Nusse for 1 year.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.